US FDA Biosimilars Acting Director Yim ‘Not A Great Fan’ Of Suffix-Based Naming Policy

 
• By Sue Sutter
  
question-mark-tiles_762800164
Biosimilars program acting director Sarah Yim said she questioned the need for distinguishable, nonproprietary names for biosimilars.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics